• Publications
  • Influence
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patientExpand
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
TLDR
Estimates of expected health outcomes for larger societies are included, where data exist, and the level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to pre-defined scales. Expand
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
TLDR
The current manuscript is an update of the original Practical Guide, published in June 2013, and listed 15 topics of concrete clinical scenarios for which practical answers were formulated, based on available evidence. Expand
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.
TLDR
New oral anticoagulant drugs are an alternative for vitamin K antagonists to prevent stroke in patients with non-valvular atrial fibrillation (AF) and many unresolved questions on how to optimally use these drugs in specific clinical situations remain. Expand
Task Force on Sudden Cardiac Death of the European Society of Cardiology.
TLDR
The members of the Task Force on Sudden Death dedicate this paper to the memory of their former friend and colleague, Professor Ronald W. F. Campbell, who spent his life working in the field of sudden cardiac death, and the extent of the expanding knowledge in this field is described. Expand
Drug induced QT prolongation and torsades de pointes
TLDR
In 1966, Francois Dessertenne described a specific electrocardiographic form of polymorphic ventricular tachycardia, which he termed “torsades de pointes” (TdP) and, until recently, there has been considerable conjecture as to the pathophysiology of this arrhythmia. Expand
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
TLDR
Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice, particularly in patients newly started on antICOagulation. Expand
Resting heart rate in cardiovascular disease.
TLDR
It seems desirable to maintain resting HR substantially below the traditionally defined tachycardia threshold of 90 or 100 beats/min, which may be difficult to define an optimal HR for a given individual. Expand
...
1
2
3
4
5
...